Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease

Charles T. Quinn, Marie J. Stuart, Karen Kesler, Kenneth Ataga, Winfred C. Wang, Lori Styles, Kim Smith-Whitley, Ted Wun, Ashok Raj, Lewis L. Hsu, Suba Krishnan, Frans A. Kuypers, Yamaja Setty, Seungshin Rhee, Nigel S. Key, George R. Buchanan

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Tapered oral dexamethasone for acute chest syndrome (ACS) in sickle cell anaemia was studied using a novel ACS assessment tool and investigational biomarkers. Twelve participants were randomized (mean age 17·3years) before early study termination. Dexamethasone decreased duration of hospitalization for ACS by 20·8h compared to placebo (P=0·024). Rebound pain occurred in both groups (3 dexamethasone versus 1 placebo). Overall, dexamethasone decreased the leucocyte activation biomarker, sL-selectin; however, participants with rebound pain had higher sL-selectin within 24h of treatment (dexamethasone or placebo). This ACS assessment tool was feasibly applied, and sL-selectin is a promising biomarker of ACS therapy.

Original languageEnglish (US)
Pages (from-to)263-267
Number of pages5
JournalBritish Journal of Haematology
Volume155
Issue number2
DOIs
StatePublished - Oct 1 2011

Fingerprint

Acute Chest Syndrome
Sickle Cell Anemia
Dexamethasone
Selectins
Biomarkers
Placebos
Pain
Hospitalization
Leukocytes
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Quinn, C. T., Stuart, M. J., Kesler, K., Ataga, K., Wang, W. C., Styles, L., ... Buchanan, G. R. (2011). Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. British Journal of Haematology, 155(2), 263-267. https://doi.org/10.1111/j.1365-2141.2011.08827.x

Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. / Quinn, Charles T.; Stuart, Marie J.; Kesler, Karen; Ataga, Kenneth; Wang, Winfred C.; Styles, Lori; Smith-Whitley, Kim; Wun, Ted; Raj, Ashok; Hsu, Lewis L.; Krishnan, Suba; Kuypers, Frans A.; Setty, Yamaja; Rhee, Seungshin; Key, Nigel S.; Buchanan, George R.

In: British Journal of Haematology, Vol. 155, No. 2, 01.10.2011, p. 263-267.

Research output: Contribution to journalArticle

Quinn, CT, Stuart, MJ, Kesler, K, Ataga, K, Wang, WC, Styles, L, Smith-Whitley, K, Wun, T, Raj, A, Hsu, LL, Krishnan, S, Kuypers, FA, Setty, Y, Rhee, S, Key, NS & Buchanan, GR 2011, 'Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease', British Journal of Haematology, vol. 155, no. 2, pp. 263-267. https://doi.org/10.1111/j.1365-2141.2011.08827.x
Quinn, Charles T. ; Stuart, Marie J. ; Kesler, Karen ; Ataga, Kenneth ; Wang, Winfred C. ; Styles, Lori ; Smith-Whitley, Kim ; Wun, Ted ; Raj, Ashok ; Hsu, Lewis L. ; Krishnan, Suba ; Kuypers, Frans A. ; Setty, Yamaja ; Rhee, Seungshin ; Key, Nigel S. ; Buchanan, George R. / Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. In: British Journal of Haematology. 2011 ; Vol. 155, No. 2. pp. 263-267.
@article{da735e48478d43568c61e729e8ef413c,
title = "Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease",
abstract = "Tapered oral dexamethasone for acute chest syndrome (ACS) in sickle cell anaemia was studied using a novel ACS assessment tool and investigational biomarkers. Twelve participants were randomized (mean age 17·3years) before early study termination. Dexamethasone decreased duration of hospitalization for ACS by 20·8h compared to placebo (P=0·024). Rebound pain occurred in both groups (3 dexamethasone versus 1 placebo). Overall, dexamethasone decreased the leucocyte activation biomarker, sL-selectin; however, participants with rebound pain had higher sL-selectin within 24h of treatment (dexamethasone or placebo). This ACS assessment tool was feasibly applied, and sL-selectin is a promising biomarker of ACS therapy.",
author = "Quinn, {Charles T.} and Stuart, {Marie J.} and Karen Kesler and Kenneth Ataga and Wang, {Winfred C.} and Lori Styles and Kim Smith-Whitley and Ted Wun and Ashok Raj and Hsu, {Lewis L.} and Suba Krishnan and Kuypers, {Frans A.} and Yamaja Setty and Seungshin Rhee and Key, {Nigel S.} and Buchanan, {George R.}",
year = "2011",
month = "10",
day = "1",
doi = "10.1111/j.1365-2141.2011.08827.x",
language = "English (US)",
volume = "155",
pages = "263--267",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease

AU - Quinn, Charles T.

AU - Stuart, Marie J.

AU - Kesler, Karen

AU - Ataga, Kenneth

AU - Wang, Winfred C.

AU - Styles, Lori

AU - Smith-Whitley, Kim

AU - Wun, Ted

AU - Raj, Ashok

AU - Hsu, Lewis L.

AU - Krishnan, Suba

AU - Kuypers, Frans A.

AU - Setty, Yamaja

AU - Rhee, Seungshin

AU - Key, Nigel S.

AU - Buchanan, George R.

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Tapered oral dexamethasone for acute chest syndrome (ACS) in sickle cell anaemia was studied using a novel ACS assessment tool and investigational biomarkers. Twelve participants were randomized (mean age 17·3years) before early study termination. Dexamethasone decreased duration of hospitalization for ACS by 20·8h compared to placebo (P=0·024). Rebound pain occurred in both groups (3 dexamethasone versus 1 placebo). Overall, dexamethasone decreased the leucocyte activation biomarker, sL-selectin; however, participants with rebound pain had higher sL-selectin within 24h of treatment (dexamethasone or placebo). This ACS assessment tool was feasibly applied, and sL-selectin is a promising biomarker of ACS therapy.

AB - Tapered oral dexamethasone for acute chest syndrome (ACS) in sickle cell anaemia was studied using a novel ACS assessment tool and investigational biomarkers. Twelve participants were randomized (mean age 17·3years) before early study termination. Dexamethasone decreased duration of hospitalization for ACS by 20·8h compared to placebo (P=0·024). Rebound pain occurred in both groups (3 dexamethasone versus 1 placebo). Overall, dexamethasone decreased the leucocyte activation biomarker, sL-selectin; however, participants with rebound pain had higher sL-selectin within 24h of treatment (dexamethasone or placebo). This ACS assessment tool was feasibly applied, and sL-selectin is a promising biomarker of ACS therapy.

UR - http://www.scopus.com/inward/record.url?scp=80053570618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053570618&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2011.08827.x

DO - 10.1111/j.1365-2141.2011.08827.x

M3 - Article

VL - 155

SP - 263

EP - 267

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -